About Replimune Group, Inc.
https://www.replimune.comReplimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer.
CEO
Sushil Patel
Compensation Summary
(Year 2025)
ETFs Holding This Stock
Summary
Showing Top 3 of 99
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
Jefferies
Buy
Leerink Partners
Outperform
Wedbush
Outperform
Cantor Fitzgerald
Overweight
Piper Sandler
Overweight
Grade Summary
Showing Top 6 of 9
Price Target
Institutional Ownership
BAKER BROS. ADVISORS LP
Shares:11.05M
Value:$85.16M
PRICE T ROWE ASSOCIATES INC /MD/
Shares:8.31M
Value:$64.04M
RTW INVESTMENTS, LP
Shares:6.4M
Value:$49.31M
Summary
Showing Top 3 of 184
About Replimune Group, Inc.
https://www.replimune.comReplimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q2-2026 | $0 | $84.29M ▼ | $-83.1M ▲ | 0% | $-0.9 ▲ | $-82.04M ▲ |
| Q1-2026 | $0 | $90.42M ▲ | $-86.69M ▼ | 0% | $-0.95 ▲ | $-89.43M ▼ |
| Q4-2025 | $0 | $79.03M ▲ | $-74.13M ▼ | 0% | $-0.96 ▼ | $-71.95M ▼ |
| Q3-2025 | $0 | $66.02M ▲ | $-66.34M ▼ | 0% | $-0.79 ▼ | $-64.95M ▼ |
| Q2-2025 | $0 | $58.92M | $-53.05M | 0% | $-0.68 | $-57.58M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q2-2026 | $323.64M ▼ | $389.45M ▼ | $126.11M ▼ | $263.34M ▼ |
| Q1-2026 | $403.34M ▼ | $469.51M ▼ | $132.79M ▼ | $336.71M ▼ |
| Q4-2025 | $483.8M ▼ | $551.33M ▼ | $135.49M ▲ | $415.84M ▼ |
| Q3-2025 | $536.54M ▲ | $603.63M ▲ | $121.25M ▲ | $482.37M ▲ |
| Q2-2025 | $432.06M | $498.2M | $116.74M | $381.46M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q2-2026 | $-83.1M ▲ | $-81.21M ▼ | $84.17M ▲ | $324K ▲ | $4.92M ▲ | $-82.56M ▼ |
| Q1-2026 | $-86.69M ▼ | $-77.02M ▼ | $65.05M ▲ | $-158K ▼ | $-13.74M ▲ | $-79.76M ▼ |
| Q4-2025 | $-74.13M ▼ | $-53.73M ▼ | $-7.7M ▲ | $-132K ▼ | $-61.12M ▼ | $-54.87M ▼ |
| Q3-2025 | $-66.34M ▼ | $-50.71M ▼ | $-46.32M ▼ | $155.93M ▲ | $58.75M ▲ | $-52.51M ▼ |
| Q2-2025 | $-53.05M | $-38.64M | $458K | $-39K | $-38.16M | $-40.72M |
CEO
Sushil Patel
Compensation Summary
(Year 2025)
ETFs Holding This Stock
Summary
Showing Top 3 of 99
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
Jefferies
Buy
Leerink Partners
Outperform
Wedbush
Outperform
Cantor Fitzgerald
Overweight
Piper Sandler
Overweight
Grade Summary
Showing Top 6 of 9
Price Target
Institutional Ownership
BAKER BROS. ADVISORS LP
Shares:11.05M
Value:$85.16M
PRICE T ROWE ASSOCIATES INC /MD/
Shares:8.31M
Value:$64.04M
RTW INVESTMENTS, LP
Shares:6.4M
Value:$49.31M
Summary
Showing Top 3 of 184